MedTrace Logo

Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:

NCT04695704 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2024-07-03

No results posted yet for this study

Summary

Recently, a new clinical presentation called "long covid" has been reported, for patients with symptoms lasting for more than 4 weeks from the onset of the disease. Typically, the symptoms comprise dyspnea, cough, headache, arthralgia, fever, abdominal pain, asthenia and skin manifestations This project aims to evaluate the efficacy of Montelukast in improving the quality of life associated with respiratory symptoms in patients with persistent COVID-19 symptoms. The main objective is to compare the efficacy of low-dose Montelukast versus placebo to improve respiratory symptoms in patients with persistent COVID-19 symptoms.

Conditions

  • Covid19
  • SARS (Disease)

Interventions

DRUG

Montelukast

10 mg oral montelukast once daily for 28 days

OTHER

placebo

10 mg oral placebo once daily for 28 days

Sponsors & Collaborators

  • Institut Català de la Salut

    collaborator OTHER

  • Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

    lead OTHER

Principal Investigators

  • Jesus Almeda Ortega, PhD · Institut Català de la Salut

  • Sara Bonet Monne, PhD · Institut Català de la Salut

  • Betlem Salvador Gonzalez, PhD · Institut Català de la Salut

  • Francisco Mera Cordero, MD · Institut Català de la Salut

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2023-07-24
Completion
2023-08-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04695704 on ClinicalTrials.gov